Global H1 Adrenoleukodystrophy Pipeline Market Overview of Companies and Drug Profile H1 2017

Global adrenoleukodystrophy therapeutics pipeline report 2017 report provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Adrenoleukodystrophy Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Companies Involved in Therapeutics  - bluebird bio Inc, MedDay SA, Minoryx Therapeutics sl, Pfizer Inc, ReceptoPharm Inc, Viking Therapeutics Inc

Drug Profile: biotin, DRX-065, DUOC-01, Lenti-D, MGTA-456, MIN-102, OP-101, pioglitazone hydrochloride, RPI-78M, temsirolimus, VK-0214, VK-2809

Discount Available at http://www.reportsnreports.com/contacts/discount.aspx?name=1010763  (This report is available at upto 25% Discount till June 02^nd 2017.)

Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Order a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=1010763

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope – The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders). The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders).

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details at [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need. ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more.